Are You Looking for a Top Momentum Pick? Why Karyopharm Therapeutics (KPTI) is a Great ChoiceZacks Investment Research • 11/28/19
Karyopharm Therapeutics Inc.'s (KPTI) CEO Michael Kauffman on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/04/19
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c) (4).GlobeNewsWire • 10/01/19
Even More Implied Analyst Upside for Karyopharm Therapeutics After Royalty Pact24/7 Wall Street • 09/17/19
Karyopharm Enters Into Royalty Agreement with Healthcare Royalty Partners for up to $150 MillionGlobeNewsWire • 09/16/19
Karyopharm Announces XPOVIO™ (Selinexor) Presentations at the 17th International Myeloma WorkshopGlobeNewsWire • 09/13/19
Karyopharm Announces Publication of XPOVIO™ (Selinexor) Phase 2b STORM Study Results in The New England Journal of MedicineGlobeNewsWire • 08/21/19
Karyopharm Therapeutics Inc. (KPTI) CEO Dr. Michael Kauffman on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/06/19
Earnings Preview: Karyopharm Therapeutics (KPTI) Q2 Earnings Expected to DeclineZacks Investment Research • 07/30/19
Karyopharm's FDA Accelerated Approval For Cancer Drug Isn't The Only One On DeckSeeking Alpha • 07/09/19
Why Investors In This Biotech Stock Are Breathing A Sigh Of ReliefInvestors Business Daily • 07/05/19
Karyopharm's stock soars to lead Nasdaq gainers before halt; XPOVIO gets FDA approvalMarket Watch • 07/03/19